pentazocine (Talwin)
Jump to navigation
Jump to search
Introduction
Tradename: Talwin. DEA-controlled substance: class 4.
Dosage
Tabs: 50 mg.
Pharmacokinetics
- extensive 1st pass metabolism in liver
- 3-15% excreted unchanged in the urine
- racemic mixture; L-isomer is analgesic form
elimination via liver
1/2life = 2-7 hours
protein binding = 60-70 %
elimination by hemodialysis = +
Adverse effects
- sedation
- sweating
- dizziness
- nausea
- psychometric effects
- autonomic crisis (at high doses)
- may result in immediate withdrawal symptoms in opiate- dependent patients[3]
- high incidence of delirium in elderly patients[3]
- drug adverse effects of opiates
- drug adverse effects of psychotropic agents
- drug adverse effects of sedatives
Laboratory
- specimen: serum, plasma (EDTA), urine
- methods: GLC, GC-MS, fluorometry, RIA
- interferences:
- metabolites interfere with fluorometric assay
- acid hydrolysis modifies structure; deconjugation must be performed enzymatically
More general terms
Component of
- acetaminophen/pentazocine (Talacen)
- naloxone/pentazocine (Talwin NX)
- aspirin/pentazocine (Talwin Compound)
References
- ↑ The Pharmacological Basis of Therapeutics, 9th ed. Gilman et al, eds. Permagon Press/McGraw Hill, 1996
- ↑ Clinical Guide to Laboratory Tests, 3rd ed. Teitz ed., W.B. Saunders, 1995
- ↑ Jump up to: 3.0 3.1 3.2 Geriatrics Review Syllabus, American Geriatrics Society, 5th edition, 2002-2004
Database
- PubChem: http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=4736
- PubChem: http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=441278
- PubChem: http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=9669
- PubChem: http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=198520
- PubChem: http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=107799
- PubChem: http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=656697
- PubChem: http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=441277
- PubChem: http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=66386